[
    [
        {
            "time": "2019-04-15",
            "original_text": "Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Altria",
                    "Becton Dickinson"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "consumer goods",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-23",
            "original_text": "Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement",
            "features": {
                "keywords": [
                    "Lilly",
                    "conference call",
                    "financial results"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-16",
            "original_text": "Is AstraZeneca Stock Worth Buying Before Earnings?",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "stock",
                    "earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Is AstraZeneca Stock Worth Buying Before Earnings?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-18",
            "original_text": "Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice",
            "features": {
                "keywords": [
                    "growth stock",
                    "Lilly",
                    "solid choice"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-20",
            "original_text": "Why Eli Lilly (LLY) is a Great Dividend Stock Right Now",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "dividend stock"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Eli Lilly (LLY) is a Great Dividend Stock Right Now",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-25",
            "original_text": "Sanofi sets a fixed price of insulin at $99 per month for some patients",
            "features": {
                "keywords": [
                    "Sanofi",
                    "insulin",
                    "fixed price"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Sanofi sets a fixed price of insulin at $99 per month for some patients",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-27",
            "original_text": "Sanofi to cut U.S. insulin costs for some patients to $99 per month",
            "features": {
                "keywords": [
                    "Sanofi",
                    "insulin",
                    "costs"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Sanofi to cut U.S. insulin costs for some patients to $99 per month",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]